Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a 5% revenue growth and a 2% improvement in gross margins, indicating strong financial performance. Additionally, net income increased by 10%, and cash flow from operations rose by 12%, showcasing operational efficiency. The lack of major risks or negative trends in the Q&A further supports a positive outlook. Despite the absence of strategic initiatives and shareholder return discussions, the financial improvements suggest a positive stock price movement in the short term.
Key Financial Performance
Revenue $30.5 million, a 5% increase year-over-year, driven by strong demand for our preclinical products.
Gross Margin 62%, an improvement of 2 percentage points year-over-year, attributed to operational efficiencies and favorable product mix.
Operating Expenses $15 million, a 3% increase year-over-year, primarily due to investments in R&D and sales initiatives.
Net Income $3.2 million, up 10% year-over-year, reflecting higher revenue and improved gross margins.
Cash Flow from Operations $4.5 million, a 12% increase year-over-year, supported by better working capital management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-looking statements: The company's forward-looking statements are subject to risks, uncertainties, and contingencies that could cause actual results to differ materially from those expressed or implied. This includes potential impacts on future events or financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Accounting Officer
Benchmark LLC
Biosciences Inc
Bruce Jackson
CEO Director
CFO Treasurer
Conference Instructions
Director Frost
Division Bruce
Division day
Duke President
EDT Knight
Ellipsis TA
Frost CFO
Harvard Biosciences
Inc Conference
Instructions Vice
Jackson Benchmark
KeyBanc Capital
Knight KeyBanc
LLC Research
Markets Inc
Officer EDT
Officer Principal
President CEO
President Ellipsis
Principal Accounting
Principal Financial
Treasurer Principal
day Harvard
HBIO Transcript
Harvard Bioscience, Inc. (HBIO) Q1 2026 Earnings Call Transcript
Positive5-12
The earnings call highlights a 5% revenue growth and a 2% improvement in gross margins, indicating strong financial performance. Additionally, net income increased by 10%, and cash flow from operations rose by 12%, showcasing operational efficiency. The lack of major risks or negative trends in the Q&A further supports a positive outlook. Despite the absence of strategic initiatives and shareholder return discussions, the financial improvements suggest a positive stock price movement in the short term.
Harvard Bioscience, Inc. (HBIO) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call presents mixed signals: while Q4 revenue declined due to external factors like a government shutdown, gross margins and EBITDA improved due to cost reductions. The Q&A reveals potential growth in key product lines and a strong backlog. However, uncertainties like NIH funding delays and macroeconomic risks persist. The company's flexible debt structure and positive guidance for 2026 products are offset by operational risks from facility consolidation and increased employee compensation costs. Overall, the sentiment is neutral, with no strong catalysts for significant stock price movement.
OceanaGold Corporation (OGC:CA) Q3 2025 Earnings Call Transcript
Positive11-7
The earnings call reflects a positive sentiment with strong financial performance, including increased EBITDA, net profit, and EPS. Despite some uncertainties in CapEx and costs, the company shows confidence in resolving issues and improving production. The anticipated strong Q4 and optimistic 2026 outlook, alongside potential cost reductions and share buybacks, support a positive stock price movement.
Harvard Bioscience, Inc. (HBIO) Q3 2025 Earnings Call Transcript
Unknown11-7
The earnings call presents a mixed picture. Financial performance shows positive elements like high gross margins and improved EBITDA, yet revenue declined YoY. Challenges such as NIH funding delays, China market struggles, and tariff impacts create uncertainties. However, optimistic guidance and product development initiatives provide potential upside. The Q&A reveals cautious optimism but highlights risks like NIH funding delays. Overall, the sentiment is neutral due to balanced positive and negative factors, with no strong catalysts to drive significant stock price movement in the short term.
HBIO Slides
Harvard Bioscience Q4 2025 slides: margins hit 7-quarter high2026-03-12
Harvard Bioscience Q3 2025 slides: EPS miss overshadows operational improvements2025-11-06
Harvard Bioscience Q2 2025 slides: improved profitability despite revenue challenges2025-08-11
Harvard Bioscience Q1 2025 slides: Revenue decline and goodwill impairment weigh on results2025-05-12
HBIO Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
